Home › Funds › BAKER BROS. ADVISORS LP › EWTX
BAKER BROS. ADVISORS LP position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 3,701,719 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$150.4M, representing 0.79% of its reported portfolio and ranking #21 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed EWTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's EWTX position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in EWTX in Q3 2023 at 1,049,699 shares (US$6.0M). The position peaked in Q1 2026 at 6,575,940 shares, worth US$207.1M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 3,701,719 shares valued at US$150.4M — a reduction of -2,874,221 shares quarter over quarter.. Notable position changes include a 197% increase in Q4 2023 (shares rose 67% over the following quarter), a 88% increase in Q1 2024 (shares fell 1% over the following quarter), a 44% trim in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.05M | $6.01M | New |
| Q4 2023 | 3.11M | $34.05M | Add |
| Q1 2024 | 5.84M | $106.52M | Add |
| Q2 2024 | 5.84M | $105.18M | Hold |
| Q3 2024 | 5.84M | $155.87M | Hold |
| Q4 2024 | 6.16M | $164.36M | Add |
| Q1 2025 | 6.16M | $135.43M | Hold |
| Q2 2025 | 7.31M | $95.78M | Add |
| Q3 2025 | 7.31M | $118.50M | Hold |
| Q4 2025 | 6.58M | $163.18M | Reduce |
| Q1 2026 | 6.58M | $207.14M | Hold |
| Q2 2026 | 3.70M | $150.40M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.52M · Q2 2026
- Paradigm Biocapital Advisors LP 10.22M sh · $415.05M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.73M sh · $192.12M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- Siren, L.L.C. 3.18M sh · $129.39M · Q2 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- Integral Health Asset Management, LLC 2.00M sh · $81.26M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- MPM BioImpact LLC 1.62M sh · $65.85M · Q2 2026
- First Light Asset Management, LLC 1.10M sh · $44.50M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held EWTX?
BAKER BROS. ADVISORS LP has disclosed EWTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in EWTX?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 3.70M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $150.40M, representing 0.79% of its reported portfolio and ranking #21.
Has BAKER BROS. ADVISORS LP been buying or selling EWTX?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP reduced its position in EWTX. The position peaked in Q1 2026 at 6.58M shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.